Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
P20594
UPID:
ANPRB_HUMAN
Alternative names:
Atrial natriuretic peptide receptor type B; Guanylate cyclase B
Alternative UPACC:
P20594; B0ZBF2; B0ZBF3; D3DRP3; D3DRP4; O60871; Q4VAK7; Q5TCV2; Q8TA93; Q9UQ50
Background:
Atrial natriuretic peptide receptor 2, also known as Guanylate cyclase B, plays a pivotal role in skeletal growth regulation. It acts as a receptor for the C-type natriuretic peptide NPPC/CNP hormone, triggering guanylate cyclase activity upon ligand binding.
Therapeutic significance:
Linked to diseases such as Acromesomelic dysplasia 1, Epiphyseal chondrodysplasia, Miura type, and Short stature with non-specific skeletal abnormalities, understanding the role of Atrial natriuretic peptide receptor 2 could open doors to potential therapeutic strategies.